Amneal Pharmaceuticals, Inc. (AMRX) Q3 2023 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET

Company Participants

Anthony DiMeo - Head-Investor Relations
Chirag Patel - Co-Founder & Co-Chief Executive Officer
Chintu Patel - Co-Founder & Co-Chief Executive Officer
Tasos Konidaris - Chief Financial Officer
Joe Renda - Senior Vice President & Chief Commercial Officer-Specialty
Harsher Singh - Senior Vice President-Biosciences

Conference Call Participants

Leszek Sulewski - Truist
Balaji Prasad - Barclays

Operator

Good morning, and welcome to the Amneal Third Quarter 2013 Earnings Call. I will now turn the call over to Amneal Head of Investor Relations, Anthony DiMeo.

Anthony DiMeo

Good morning, and thank you for joining Amneal Pharmaceuticals Third Quarter 2023 Earnings Call. Today, we issued a press release reporting our Q3 results. We announced certain unaudited preliminary results for Q3 on October 23. Our earnings press release and presentation are available at amneal.com.

Certain statements made on this call regarding matters that are not historical facts, including, but not limited to management's outlook or predictions are forward-looking statements, that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward-Looking Statements in the earnings presentation and our SEC filings for a discussion of factors that may impact our future performance. We also discuss non-GAAP measures. Information on our use of these measures and reconciliations to US GAAP are in the earnings presentation.

On the call today are Chirag and Chintu Patel, Co-Founders and Co-CEOs, Tasos Konidaris, CFO; our commercial leaders, Andy Boyer for Generics, Joe Renda for Specialty, Harsher Singh for Biosciences; and Jason Daly, Chief Legal Officer.

I will now hand the call over to Chirag.

Chirag Patel

Thank you, Tony and good morning everyone. We delivered another very strong quarter with $620 million of revenue, which is up 14%, adjusted EBITDA